Dose-finding Study of Abraxane in Combination With Cisplatin to Treat Advanced Nasopharyngeal Carcinoma (ABX-DDP-Dose)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01735409
Recruitment Status : Unknown
Verified January 2014 by Li Zhang, Sun Yat-sen University.
Recruitment status was:  Active, not recruiting
First Posted : November 28, 2012
Last Update Posted : January 28, 2014
Information provided by (Responsible Party):
Li Zhang, Sun Yat-sen University

Brief Summary:
This is a single center, non-randomized phase IIa study to determine the tolerance and safety of Abraxane (ABX) in combination with cisplatin (DDP) in patients with advanced nasopharyngeal carcinoma (NPC). Patients in whom the standard therapy had failed or had been infeasible will be eligible.The safety and efficacy will be evaluated according to NCI-CTCAE V4.0 and RECIST 1.1 respectively.

Condition or disease Intervention/treatment Phase
Nasopharyngeal Neoplasms Drug: ABX + DDP Phase 1 Phase 2

Detailed Description:
Nasopharyngeal carcinoma (NPC) is most commonly seen in Southeast Asia, especially in southern and southeastern China, where the incidence rate has been documented between 10 and 150 cases per 100,000 population per year. For advanced or metastatic NPC, chemotherapy remain the mainstay of treatment. The 130-nm albumin-bound formulation of paclitaxel ([Abraxane, ABX ];Celgene,Summit,NJ) is a promising new agent with more efficient entry to the tumor microenvironment via caveolae-mediated transcytosis and preferential uptake by cancer cells. Superior activity of ABX-based regimens without the necessity for antianaphylactic pretreatments been shown in various solid tumors compared with the traditional solvent-based paclitaxel-based ones. However, the safety and efficacy of combination of ABX and cisplatin (DDP) has not been determined in patients with advanced NPC. In this single center, non-randomized phase IIa study, investigators seek to determine the maximum tolerated dose (MTD) and dose limiting toxicity (DLT) of ABX-DDP, and perform an exploratory study of its efficacy as measured by tumor response.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 69 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Single Center Phase IIa Study of Nanoparticle Albumin-bound Paclitaxel in Combination With Cisplatin in Advanced Nasopharyngeal Carcinoma
Study Start Date : November 2012
Estimated Primary Completion Date : March 2014
Estimated Study Completion Date : June 2014

Resource links provided by the National Library of Medicine

Drug Information available for: Cisplatin

Arm Intervention/treatment
Experimental: 1-day regimen
ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1
Drug: ABX + DDP
ABX 260 mg/m2 day 1 + DDP 75mg/m2 day 1

Experimental: 2-day regimen
ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1
Drug: ABX + DDP
ABX 140 mg/m2 day 1,8 + DDP 75mg/m2 day 1

Experimental: 3-day regimen
ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1
Drug: ABX + DDP
ABX 100 mg/m2 day 1,8,15 + DDP 75mg/m2 day 1

Primary Outcome Measures :
  1. Objective response rate (ORR) [ Time Frame: 24 months ]

Secondary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: 24 months ]
  2. Number of Participants with Adverse Events [ Time Frame: 24 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically proven NPC diagnosis
  • Patients who failed the prior standard treatment or were intolerant of standard treatment
  • Elder than 18 years old
  • Performance status 0-2
  • Patients previously treated with chemotherapy (those having received paclitaxel-based regimen were not excluded)
  • Subjects with at least one measurable lesion (Tumor lesions that are situated in a previously irradiated area could not be considered measurable).
  • Life expectancy over twelve weeks
  • Neutrophil > 1.5X10^9/L, PLT > 100X10^9/L, Hb ≥ 90 g/l, with normal hepatic function(AST, ALT < 2.5 x upper limit of normal , and bilirubin < 1.0 x upper limit of normal), with normal renal function (creatinine < 1.5 x upper limit of normal or creatinine clearance ≥ 60ml/min as calculated by the Cockcroft - Gault formula. )
  • Urine pregnancy test (-) within 1 weeks before enrollment or being able to take effective contraceptive measures during the medication and six months after completion of the trial for fertile women.
  • Being able to provide paraffin blocks or 5-7 slides of biopsy tumor tissues.
  • Amenable to regular follow-up and to comply with trial requirements.
  • Signed and dated informed consent before the start of specific protocol procedures

Exclusion Criteria:

  • History of allergy to paclitaxel or docetaxel
  • Patient with central nervous system metastasis
  • Patient refusing participation or signing informed consent
  • Active clinically serious infections with an anticipated antibiotics treatment for more than 4 weeks
  • Patient with life threatening medical condition such as congestive heart failure, symptomatic coronary artery disease or heart block
  • Myocardial infarction that occurred within 3 months before enrollment
  • Had received chemotherapy, radiotherapy or other anti-cancer therapies within 3 weeks before enrollment
  • With a pre-existing peripheral neuropathy (National Cancer Institute Common Toxicity Criteria for Adverse Events [NCI CTC] grade ≥ 2)
  • Previously received post-2nd line anti-cancer therapy
  • Previous or concurrent cancer that is distinct in primary site or histology from the cancer being evaluated in this study EXCEPT cervical carcinoma in situ, treated basal cell carcinoma, superficial bladder tumors[Ta, Tis & T1] or any cancer curatively treated > 3 years prior to study entry.
  • History of immunodeficiency , including HIV testing positive or suffering from other acquired and congenital immunodeficiency disease, or the history of organ transplants;
  • Patients receiving prior abraxane treatment during pregnancy or lactation period
  • Fertile women who failed to or are reluctant to take contraceptive measures or pregnancy test
  • Men or his companion who are reluctant to take effective contraceptive measures during the medication and six months after completion of the trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01735409

China, Guangdong
Cancer Center, Sun Yat-sen University
Guangzhou, Guangdong, China, 510060
Sponsors and Collaborators
Sun Yat-sen University
Principal Investigator: Li Zhang, MD Sun Yat-sen University

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Li Zhang, Professor, Sun Yat-sen University Identifier: NCT01735409     History of Changes
Other Study ID Numbers: ABXDDP20101224
First Posted: November 28, 2012    Key Record Dates
Last Update Posted: January 28, 2014
Last Verified: January 2014

Keywords provided by Li Zhang, Sun Yat-sen University:
Advanced Nasopharyngeal Carcinoma

Additional relevant MeSH terms:
Nasopharyngeal Neoplasms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Pharyngeal Neoplasms
Otorhinolaryngologic Neoplasms
Head and Neck Neoplasms
Neoplasms by Site
Nasopharyngeal Diseases
Pharyngeal Diseases
Stomatognathic Diseases
Otorhinolaryngologic Diseases
Albumin-Bound Paclitaxel
Antineoplastic Agents